Glutamate receptor modulators and therapeutic agents
View Patent ↗The present invention discloses methods of modulating the activity of Group I mGluRs using a defined class of benzamide compounds. In one embodiment, methods of modulating the activity of mGluR1 are provided. In another embodiment, methods of modulating the activity of mGluR5 are provided. In still another embodiment, methods of simultaneously modulating the activities of both mGluR1 and mGluR5 are provided. The present invention also provides methods of treating diseases or disorders which are mediated in full or in part by Group I mGluRs using one or more compounds belonging to the defined class of benzamide compounds. The present invention further provides methods of preventing diseases or disorders which are mediated in full or in part by Group I mGluRs using one or more compounds belonging to the defined class of compounds.
1. A method of treating pain by administering a noncompetitive Group 1 mGluR negative allosteric modulator compound, its pharmaceutically acceptable salts, prodrugs, or pharmaceutically acceptable salts of its prodrugs to an animal wherein said compound has the formula:
2. The method of claim 1 wherein said pain is acute or chronic pain.
3. The method of claim 1 wherein said pain is selected from the group consisting of bone and joint pain, repetitive motion pain, dental pain, cancer pain, myofacial pain, perioperative pain, chronic pain, neuropathic pain, post-traumatic pain, trigeminal neuralgia, migraine and migraine headache, neuropathic pain, diabetic neuropathy, entrapment neuropathy, phantom pain, thalamic pain after stroke, post-herpetic neuralgia, atypical facial neuralgia pain after tooth extraction, pain from spinal cord injury, trigeminal neuralgia and cancer pain resistant to narcotic analgesics.
4. The method of claim 1 wherein said pain is diabetic neuropathy.
5. The method of claim 1 wherein said pain is neuropathic pain.